Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials
| Autor: | Ronald Goldenberg, Peter Sartipy, Glenn M. Chertow, Bergur V. Stefánsson, C. David Sjöström, Valerie A. Cain, Robert D. Toto |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
endocrine system
medicine.medical_specialty Endocrinology Diabetes and Metabolism Population Urology 030209 endocrinology & metabolism 030204 cardiovascular system & hematology Placebo Hypomagnesemia law.invention Placebos 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Endocrinology Randomized controlled trial Glucosides law Post-hoc analysis Internal Medicine medicine Humans Magnesium Dapagliflozin Benzhydryl Compounds education Aged Randomized Controlled Trials as Topic education.field_of_study business.industry Middle Aged medicine.disease Confidence interval chemistry Diabetes Mellitus Type 2 Hypermagnesemia business Magnesium Deficiency |
| Zdroj: | Journal of diabetes and its complications. 33(10) |
| ISSN: | 1873-460X |
| Popis: | Hypomagnesemia (serum magnesium [Mg]0.74 mmol/L [1.8 mg/dL]) is commonly observed in patients with type 2 diabetes (T2D). This study investigated the effect of treatment with dapagliflozin 10 mg on Mg concentrations in patients with T2D.In this post hoc analysis, we used pooled data from 10 placebo-controlled studies of dapagliflozin over 24 weeks of treatment in patients with T2D. We evaluated the change in Mg in patients receiving dapagliflozin vs. placebo overall, and in subgroups with baseline hypomagnesemia and normal/hypermagnesemia (≥0.74 mmol/L [≥1.8 mg/dL]). We determined the proportion of patients with baseline hypomagnesemia who achieved Mg ≥0.74 mmol/L (≥1.8 mg/dL).A total of 4398 patients with T2D were included. The mean change from baseline to week 24 in Mg was significantly larger with dapagliflozin vs. placebo; difference, 0.06 mmol/L (95% confidence interval [CI]: 0.05, 0.06). The proportion of patients with Mg within the population reference range after 24 weeks of treatment was significantly higher with dapagliflozin vs. placebo; difference, 47.8% (95% CI: 41.4, 53.9). The proportion of patients displaying hypermagnesemia did not increase with dapagliflozin treatment.Treatment with dapagliflozin 10 mg resulted in correction of Mg concentrations in patients with T2D and hypomagnesemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect